Summary of Xiangyu Medical Conference Call Industry and Company Overview - **Company**: Xiangyu Medical - **Industry**: Medical Technology and Rehabilitation Key Points and Arguments 1. **Core Technology and Market Position**: Xiangyu Medical has been developing brain-computer interface (BCI) technology for nearly a decade, mastering core technologies such as chips and EEG information collection, establishing a unique domestic advantage, and planning to export technology externally [2][3][4] 2. **Product Launch Timeline**: The company expects to launch approximately 24 new BCI rehabilitation products between June and September 2025, with registration certificates anticipated by the end of the year [2][4] 3. **Insurance Policy Support**: Relevant medical insurance charging standards have been established in regions like Hubei (966 RMB per session) and Zhejiang (960 RMB per session), which are expected to promote industry development [2][4][14] 4. **Order Procurement Trends**: There is a recovery trend in order procurement, with expectations for continued growth in the third quarter, as both large hospitals and grassroots medical institutions increase purchases [2][5][6] 5. **Application Areas**: Current BCI products are primarily used for rehabilitation training in neurodegenerative diseases and post-stroke recovery, with future plans to integrate with exoskeleton robots and balance training products [2][7] 6. **Non-invasive Signal Acquisition**: The company’s non-invasive signal acquisition devices utilize self-developed technology, featuring 2 to 512 channels, with industry-leading parameters in signal transmission rate, common-mode rejection ratio, and signal-to-noise ratio [2][10] 7. **AI Model Development**: Xiangyu Medical has launched the VTE intelligent prevention system, achieving a 99% accuracy rate in NLP multi-data analysis and a 45% reduction in missed diagnoses [3][25] 8. **Market Expansion Plans**: The company plans to leverage existing channels and partnerships with research institutions to promote BCI products and develop embedded projects like BCI treatment centers [3][12] 9. **Employee Incentives**: An employee stock ownership plan has been introduced to incentivize R&D and marketing personnel, with specific performance targets set for revenue and registration achievements [13] 10. **Future Product Development**: New BCI products are aimed at conditions such as stroke sequelae, spinal cord injuries, Parkinson's disease, depression, sleep disorders, and autism, with a comprehensive rehabilitation treatment system being developed [19][20] Additional Important Information 1. **Cost Advantages**: Xiangyu Medical has significant cost advantages due to self-developed core algorithms and hardware, allowing for lower pricing compared to foreign competitors [16][17] 2. **Regulatory Environment**: The company anticipates obtaining the BCI registration certificate by the end of December 2025, with a typical approval cycle of around six months [8] 3. **Consumer Market Plans**: Plans for consumer-oriented BCI devices include products for motion sickness, attention monitoring, and sleep assistance, with prototypes expected to be released this year [21] 4. **Exoskeleton Robot Integration**: The integration of BCI with exoskeleton robots is expected to yield prototypes this year, with certification anticipated in 2026 [22] 5. **Technological Maturity**: Key technologies include human-computer interaction, multi-sensor fusion, and autonomous navigation, which are already mature and being applied in various rehabilitation and elderly care scenarios [24] 6. **Future R&D and Marketing Strategy**: The company is increasing its R&D and marketing personnel to support its technology layout, with a focus on traditional channels and training for new product promotion [27][28]

此前在 美敦力（2004–2023） 任职近20年 ，最终担任美洲地区副总裁 ，主导糖尿病家庭护理业务的支付策略与市场准入。其领导的跨职能团队涵盖 销售、临床支 持、健康经济学、报销、客户服务与营销 等关键部门，具备丰富的跨区域管理经验。 | 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 即将召开： | | | | | | | | 2025年6月12日，首届全球医美科技大会 | | | | | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | | | | | | 2025年5月19日 ， 康复护理公司 | Lifeward（纳斯达克代码：LFWD） | 宣布任命 | 前美敦力美洲区副总裁Mark Grant 为公司新任 | 总裁兼首席执行官 | ，自 | 2025年6月2日 | | 起正式生效。此次任命标志着Lifeward进入从技术验证向商业增长过渡的关键阶段 ...

Core Insights - The article discusses the development of MyoStep, a flexible intelligent exoskeleton system designed specifically for children with movement disorders, which aims to improve their walking ability and quality of life [1][3]. Group 1: Product Overview - MyoStep is a lightweight, form-fitting, and discreet wearable device that integrates advanced smart materials and wearable sensor technology, designed to seamlessly fit into children's daily lives [3]. - The device is particularly suitable for children with cerebral palsy, a common movement disorder affecting 1-4 out of every 1,000 newborns globally, impacting muscle control and coordination [3][4]. Group 2: Technological Innovations - MyoStep represents a significant breakthrough in pediatric gait assistance, incorporating "artificial muscles," smart fabrics, and a multi-sensor network to enhance comfort, adaptability, and safety compared to traditional exoskeletons [3][4]. - The core of MyoStep consists of a wireless sensor network embedded in flexible fabric, which monitors and transmits user motion data in real-time to determine when to provide assistance to limbs [3][4]. Group 3: Safety Features - Safety is a critical consideration in the design of MyoStep, with all electronic components and actuators isolated from the skin to prevent irritation or discomfort [3]. - The system includes temperature monitoring and an emergency shut-off feature that automatically powers down the device if the surface temperature exceeds a safe threshold, preventing overheating [3]. Group 4: Future Developments - The team is continuously optimizing MyoStep's design to ensure it can adjust as children grow, meeting long-term usage needs [4]. - This innovative achievement not only offers new hope for children with cerebral palsy but also paves the way for future developments in pediatric rehabilitation engineering [4].

北京成泉资本管理有限公司（简称"成泉资本"）于2015年7月在北京注册成立，注册资本5000万元。 成 泉资本由资产管理行业名将、原中信证券执行总经理胡继光先生创立。胡继光先生历史投资业绩优秀， 具有28年证券、期货投资经验，经历了中国股市所有的牛熊市转换，见证了新中国资本市场的诞生与成 长。公司投研团队核心成员均来自国内最知名的大型证券公司和国内最具有影响力的研究机构，投资及 研究经验丰富、投资风格稳健、市场敏锐度极高、风险控制能力出色。团队核心成员共事多年、配合默 契，具有成熟的投资理念、共同的企业文化和强大的团队凝聚力。半数投研成员为公司创始合伙人，愿 景目标一致。 成泉资本拥有专业精深的投资研究能力、开放协作的企业文化、合作共赢的利益机制以 及完善的风险控制和基础设施，坚持以客户为中心，以客户资产保值增值为己任，致力于实现客户、员 工、股东多方共赢，成为国内资本市场上有重要影响力、受人尊敬的一流专业投资机构。 成泉资本， 成就您的财富梦想！ 根据市场公开信息及5月8日披露的机构调研信息，知名私募成泉资本近期对1家上市公司进行了调研， 相关名单如下： 1）翔宇医疗 （成泉资本参与公司业绩说明会&线上交流 ...